Confronting the barriers to develop novel vaccines against brucellosis

被引：4

作者：

Oliveira, Sergio Costa ^{[1
]}

Hernan Giambartolomei, Guillermo ^{[2
,3
]}

Cassataro, Juliana ^{[2
,3
]}

机构：

[1] Univ Fed Minas Gerais, Dept Biochem & Immunol, Inst Biol Sci, Belo Horizonte, MG, Brazil

[2] Fac Farm & Bioquim, CONICET, Inst Estudios Inmunidad Humoral, Buenos Aires, DF, Argentina

[3] Univ Buenos Aires, Fac Med, Lab Inmunogenet, Hosp Clin Jose de San Martin, Buenos Aires, DF, Argentina

来源：

EXPERT REVIEW OF VACCINES | 2011年 / 10卷 / 09期

关键词：

Brucella abortus; brucellosis; DNA vaccine; live-attenuated vaccine; recombinant protein vaccine; vaccine; ZN SUPEROXIDE-DISMUTASE; PROTEIN CONFERS PROTECTION; OUTER-MEMBRANE PROTEIN; POLYMERIC BACTERIAL PROTEIN; O-POLYSACCHARIDE SYNTHESIS; ACTIVATES DENDRITIC CELLS; TOLL-LIKE RECEPTOR-4; CD8(+) T-CELLS; DNA VACCINE; BALB/C MICE;

D O I：

10.1586/ERV.11.110

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Brucellosis is an important zoonotic disease of nearly worldwide distribution. This pathogen causes abortion in domestic animals and undulant fever, arthritis, endocarditis and meningitis in humans. Currently, there is no vaccine licensed for brucellosis in humans. Furthermore, control of brucellosis in the human population relies on the control of animal disease. Available animal vaccines may cause disease and in some cases have limited efficacy. This article discusses recent studies in the development of recombinant protein, DNA and live-attenuated vaccines against brucellosis. Furthermore, we call the attention of the scientific community, government and industry professionals to the fact that for these novel vaccine initiatives to become licensed products they need to be effective in natural hosts and bypass the regulatory barriers present in several countries.

引用

页码：1291 / 1305

页数：15

共 125 条

[1]

ADAMS LG, 1990, ADV BRUCELLOSIS RES, P205

[2] Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp. [J].

Al-Mariri, A ;

Tibor, A ;

Mertens, P ;

De Bolle, X ;

Michel, P ;

Godfroid, JK ;

Walravens, K ;

Letesson, J .

INFECTION AND IMMUNITY, 2001, 69 (10) :6264-6270

[3] Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant [J].

Al-Mariri, A ;

Tibor, A ;

Mertens, P ;

De Bolle, X ;

Michel, P ;

Godefroid, J ;

Walravens, K ;

Letesson, JJ .

INFECTION AND IMMUNITY, 2001, 69 (08) :4816-4822

[4] Evasion of Toll-like receptor 5 by flagellated bacteria [J].

Andersen-Nissen, E ;

Smith, KD ;

Strobe, KL ;

Barrett, SLR ;

Cookson, BT ;

Logan, SM ;

Aderem, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (26) :9247-9252

[5]

[Anonymous], 1990, ANIMAL BRUCELLOSIS

[6]

ARAYA LN, 1989, J IMMUNOL, V143, P3330

[7] Cyclic β-1,2-glucan is a brucella virulence factor required for intracellular survival [J].

Arellano-Reynoso, B ;

Lapaque, N ;

Salcedo, S ;

Briones, G ;

Ciocchini, AE ;

Ugalde, R ;

Moreno, E ;

Moriyón, I ;

Gorvel, JP .

NATURE IMMUNOLOGY, 2005, 6 (06) :618-625

[8] The Brucella abortus S19 ΔvjbR Live Vaccine Candidate Is Safer than S19 and Confers Protection against Wild-Type Challenge in BALB/c Mice When Delivered in a Sustained-Release Vehicle [J].

Arenas-Gamboa, A. M. ;

Ficht, T. A. ;

Kahl-McDonagh, M. M. ;

Gomez, G. ;

Rice-Ficht, A. C. .

INFECTION AND IMMUNITY, 2009, 77 (02) :877-884

[9] Adjuvants designed for veterinary and human vaccines [J].

Aucouturier, J ;

Dupuis, L ;

Ganne, V .

VACCINE, 2001, 19 (17-19) :2666-2672

[10] Mice immune responses to Brucella abortus heat shock proteins -: Use of baculovirus recombinant-expressing whole insect cells, purified Brucella abortus recombinant proteins, and a vaccinia virus recombinant as immunogens [J].

Bae, JE ;

Schurig, GG ;

Toth, TE .

VETERINARY MICROBIOLOGY, 2002, 88 (02) :189-202

← 1 2 3 4 5 6 7 8 9 10 →